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Abstract
 .Enzyme replacement therapy ERT can potentially result in an immunological response to the introduced protein. The
 .immunological response by Mucopolysaccharidosis type VI MPS VI cats to recombinant human N-acetylgalactosamine
 .4-sulfatase rh4S ERT has been investigated. Plasma antibody titres to rh4S were detected in untreated MPS VI and normal
control cats, but the antibody titres to rh4S were higher in ERT treated MPS VI cats. The reactivity by cats to rh4S did not
appear to be just due to species cross reactivity, as plasma antibodies from normal control, MPS VI and MPS VI ERT cats
reacted equally with feline and human 4-sulfatase. Normal control and MPS VI human plasma also had antibody titres to
rh4S. Plasma antibodies to rh4S, from an ERT treated cat, could be temporarily removed from circulation by enzyme
infusion, confirming specificity for rh4S and indicating a possible window for ERT in the absence of antibody. In enzyme
distribution studies with 3H-rh4S, evidence of altered targeting, and enzyme inactivation and degradation were observed in
high compared to low titre rats. In high titre rats, the observed loss of 3H-label from vacuolar organelles of the liver may
represent either degradation of antibody bound 3H-rh4S for reutilisation within the liver, or antigen presentation. The
development of high titre antibody may have a detrimental effect on the efficacy of ERT. q 1997 Elsevier Science B.V.
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1. Introduction
 .1Mucopolysaccharidosis type VI MPS VI , or
 .Maroteaux-Lamy syndrome McKusick 25330 , is an
Abbreviations: CHO, Chinese hamster ovary; ERT, enzyme
replacement therapy; MPS VI, Mucopolysaccharidosis type VI;
4S, N-acetylgalactosamine 4-sulfatase; rh4S, recombinant human
4-sulfatase; 3H-rh4S, radiolabeled recombinant human 4-sulfatase
h4S, human 4-sulfatase; f4S, feline 4-sulfatase; rf4S, recombinant
feline 4-sulfatase; PBS, phosphate buffered saline; MUS, 4-meth-
ylumbelliferyl sulfate; Ig, immunoglobulin; iv, intravenous
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autosomal recessively inherited disorder which re-
sults from a deficiency in the lysosomal hydrolase
 .N-acetylgalactosamine 4-sulfatase 4S, EC 3.1.6.1 .
The archetype for MPS VI clinical presentation in-
cludes short stature, kyphosis, coarse facies, dysosto-
sis multiplex, joint stiffness, heart valve problems,
hepatosplenomegaly and corneal clouding. The onset
of clinical signs in this severe form of the disorder is
 .rapid at age F2 yr and there is severe progression
until the patient dies, usually in their early teenage
w xyears 1,2 .
The isolation and characterisation of the cDNA
 w x.sequence for human 4S h4S: 3,4 has permitted the
0925-4439r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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investigation of the molecular genetic defects giving
rise to MPS VI. The mutant alleles described thus far
w xindicate that most MPS VI mutations are unique 5 ,
suggesting that there should be a broad molecular and
clinical heterogeneity for MPS VI. A common feature
of MPS VI, is that all patients have less than 5% 4S
catalytic capacity, which is associated with a lowered
w xcellular content of 4S protein 6,7 . As almost all
patients have some detectable mutant 4S, it is ex-
pected that the patient’s immune system will have
been exposed to 4S protein, albeit mutant protein.
This is an important factor with regard to treatment
regimens which intend to replace the 4S enzyme
deficiency with a source of functional and therefore
potentially immunogenic protein.
To date several treatment regimens have been
postulated for patients with MPS and other lysosomal
w xstorage disorders 8–13 . One proposed therapy, en-
 .zyme replacement therapy ERT has been success-
fully used in correcting MPS VII in a mouse model
w x11 and clinical trials in humans with Gaucher dis-
ease have been established and have yielded promis-
w xing results 14–16 . These studies have all reported
evidence of immune reactivity to the replacement
protein in some individuals. The development of
antibodies in Gaucher patients receiving human ERT
suggests that the normal enzyme is recognized as
structurally different from the mutant protein, by the
patients immune system. Another study has reported
the evaluation of ERT in a canine model of Mu-
copolysaccharidosis type I and demonstrated antibod-
ies to a-L-iduronidase in response to enzyme infusion
w x12 . Interestingly, the treatment of lysosomal storage
disorder patients by bone marrow transplantation may
avoid the problems of antibody reactivity to the
replacement protein, as the engrafted marrow would
have already been exposed to this normal protein.
MPS VI cats have been subjected to ERT with
 .recombinant h4S rh4S , as a prelude to clinical trials
w xin human MPS VI patients 17,18 . These studies
demonstrated reduced lysosomal storage in the liver,
skin fibroblasts, aorta, heart valve and in brain
perivascular cells of MPS VI cats treated with rh4S,
w xwhen compared to untreated MPS VI controls 17,18 .
Skeletal pathology was also reduced in the MPS VI
w xERT treated cats 18 .
The administration of human enzyme into the cat
potentially raises the problem of species cross-re-
acting antibodies. Until recently, the sequence for
 w x.feline 4S f4S: 19 and therefore the expression
systems required to produce large amounts of f4S
have not been available. The sequence for f4S does
however reveal greater than 90% homology with h4S
w x19 and both have been shown to have very similar
w ximmunochemical properties 20 . A panel of seven
different conformation dependent monoclonal anti-
bodies raised against h4S showed only low reactivity
with f4S, but when first bound by a polyclonal
antibody to h4S, the f4S appeared to be conforma-
tionally altered, exposing the epitopes and allowing
similar detection of f4S and h4S with the same
w xmonoclonal antibodies 20 . This minor conformation
difference between f4S and h4S may approximate the
reported conformation difference between the mutant
h4S in MPS VI patients and the normal rh4S to be
infused during ERT.
It is postulated that a number of enzyme treated
patients will develop circulating antibodies to the
replacement protein and that antibody reactivity may
in some cases prove to be detrimental to the efficacy
of the treatment. Here we report antibodies in un-
treated normal control cats and normal control hu-
mans which both react with rh4S, and characterize
the immune response to rh4S ERT in MPS VI cats.
To investigate the effect of developing high titre
antibodies in response to ERT, the distribution and
3 .fate of radiolabeled rh4S H-rh4S was studied in a
model system using high and low titre rats.
2. Materials and methods
 . 2Polyvinylchloride plates 96 well and 75 cm
culture flasks were obtained from Costar Cambridge,
.MA, USA . Sheep anti-mouse immunoglobulin and
peroxidase labeled sheep anti-mouse immunoglobulin
reagents were purchased from Silenus Laboratories
 .Melbourne, Victoria, Australia . Goat anti-cat im-
munoglobulin and peroxidase labeled goat anti-cat
immunoglobulin were from Jackson ImmunoRe-
 .search Laboratories Inc. West Grove, PA, USA .
Rabbit anti-rat immunoglobulin and peroxidase la-
beled rabbit anti-rat immunoglobulin reagents were
purchased from Sigma Immunochemicals, Sigma-Al-
 .drich Pty. Castle Hill, New South Wales, Australia .
Sheep anti-human immunoglobulin and peroxidase
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labeled sheep anti-human immunoglobulin were from
 .Silenus Laboratories Melbourne, Victoria, Australia .
ABTS substrate kits and Affi-Gel 10 were from
 .Bio-Rad Laboratories Richmond, VA, USA and
were used according to the manufacturers’ instruc-
 .tions. 4-Methylumbelliferyl sulfate MUS was ob-
tained from Koch-Light, Haverhill, Suffolk, UK. PBS
without magnesium or calcium was from CSL Lim-
 .ited Parkville, Victoria, Australia . NCS tissue solu-
bilizer was from Amersham corporation Arlington
.Heights, IL, USA . Optiphase ‘Hi Safe 3’ liquid
scintillant and a Wallac 1409 liquid scintillation
 .counter were from Wallac Oy Turku, Finland .
2.1. Expression and purification of rh4S
The CHO-DK1 4S expression cell line was as
w xpreviously described 21 . rh4S was purified to homo-
geneity from CHO cell culture medium by im-
munoaffinity chromatography, as previously de-
w x 3scribed 17 . H-rh4S was produced in the same CHO
expression cells and was labeled with 3H-leucine
based on a method previously described for the label-
w xing of 4S in fibroblasts 22 . The ratio of radioactivity
 .  . 3dpm to 4S activity nmolrmin for the H-rh4S was
either 44 or 76 dpmrnmol per min. The specific
enzyme activity of the 3H-rh4S protein was either
49 000 or 54 000 nmolrmin per mg and the purity
w xwas assessed as previously described 17 , except that
the protein was visualized by autoradiography 70%
 .  .precursor 66 kDa and 30% mature 43, 8, 7 kDa
.4S polypeptide, with no other polypeptides observed .
2.2. Feline model for MPS VI and production of rf4S
w xA colony of MPS VI cats was established 17 ,
from a colony described by Haskins and colleagues
w x23–25 . The phenotype exhibited by homozygous
affected cats was consistent with a severe form of the
disorder and the clinical presentation observed was
w xsimilar to that of human patients with MPS VI 17 .
Homozygous MPS VI affected and heterozygous cats
were distinguished on the basis of urinary glyco-
saminoglycan screening, as developed for the diagno-
w xsis of human MPS VI patients 26 and the identifica-
w xtion of a specific genotype causing the disease 27 .
The rf4S was produced and purified as previously
w xdescribed 27 .
2.3. Infusion of rh4S and plasma sampling in cats
 .Injection of rh4S in PBS at 1–3 mgrml by i.v.
w xinfusion was as previously described 17 , usually at a
rate of 5–10 mlrkg per h, but no more than 90
mlrkg per h. One cat was treated from birth by s.c.
injection of rh4S. Plasma samples were collected as
w xpreviously described 17 . Cats suspected of exhibit-
ing immunological reactions were premedicated with
w Periactin Cyproheptadine, orally, 1–2 mg; Charles
E. Frosst Australia Pty., South Granville, N.S.W.,
. w Australia , Niramine Chlorpheniramine maleate,
subcutaneously, 1.5–2.5 mg total; Coopers Veteri-
nary Products, Silverwater, N.S.W., Australia; or
w .Piriton orally at 1–2 mg, Glaxo Australia Pty. , and
w Solucortef Hydrocortisone sodium succinate, intra-
venously, 5 mgrkg; Upjohn Pty., Rydalmere, N.S.W.,
.Australia , and were infused with rh4S at less than 5
mlrkg per h.
2.4. Immunoassay of anti-4S antibodies
An ELISA assay was used to determine the titre of
either anti-rh4S or anti-rf4S antibodies, from either
human, feline or rat plasma. A 50 ml aliquot of rh4S
 .or rf4S 10 mgrml in PBS pH 7.2 was added to
each well of a polyvinyl chloride plate and incubated
for 2 h at 378C followed by overnight incubation at
48C. The unbound 4S was aspirated from each well
and then any remaining reactive sites on the plate
blocked by three washes of 200 ml of 0.02 M
TrisrHCl, pH 7.0 containing 0.25 M NaCl and 1%
 .wrv ovalbumin. After the third wash the wells
were incubated in 200 ml of the same buffer for at
least 2 h at 208C. Test samples and control plasma
were pre-absorbed with ovalbuminrBSA coupled
Affi-Gel 10 10 mg of each protein was coupled to 1
ml of Affi-Gel 10, using the manufacturers instruc-
.tions , then serially diluted in 0.02 M TrisrHCl, pH
 .7.0 containing 0.25 M NaCl and 1% wrv ovalbu-
min and incubated on the 4S coated wells 4 h at
.208C . Each well was then aspirated and washed
three times with 200 ml of 0.02 M TrisrHCl, pH 7.0,
 .containing 0.25 M NaCl and 1% wrv ovalbumin.
Wells were then aspirated and incubated with 100 ml
of either a peroxidase-labeled goat anti-cat Ig or
peroxidase-labeled sheep anti-human Ig or peroxi-
  .dase-labeled rabbit anti-rat Ig 1r2000 dilution vrv
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in 0.02 M TrisrHCl, pH 7.0 containing 0.25 M NaCl
 . .and 1% wrv ovalbumin , for 1 h at 208C. The
unbound antibody was aspirated and the wells washed
three times in 200 ml 0.02 M TrisrHCl, pH 7.0
containing 0.25 M NaCl, before adding 100 ml per
well of a peroxidase substrate solution ABTS sub-
.strate kit . After 20 min incubation at 208C, colour
development was quantified by measuring ab-
sorbance at 414 nm on an automated ELISA reader
Ceres 900 HDi, Bio Tek Instruments, Winooski, VT,
.USA . All anti-rh4S or anti-rf4S reactivities were
compared to a negative control which determined the
reactivity of plasma with ovalbumin.
2.5. Immunoblotting of rh4S with cat and rat sera
Immunoblotting was performed as previously de-
w xscribed 6 , except that the reactivity of the cat sera
with rh4S was detected by a peroxidase-labeled goat
anti-cat Ig and the reactivity of the rat sera with rh4S
was detected by a peroxidase-labeled rabbit anti-rat
Ig.
2.6. In ˝itro enzyme uptake studies
The effect of anti-rh4S antibody on rh4S uptake
into feline fibroblasts was investigated, using plasma
 .from a treated MPS VI cat titre 1 024 000 . Feline
fibroblasts were grown to confluence in 9.6 cm2
culture wells. A 1:5 dilution of either feline plasma,
or fetal bovine serum control was incubated with
rh4S 10 or 30 nmolrminrml in complete cell cul-
.ture medium , for 5 h at 48C. 2 ml of the antibody
incubated rh4S was then added to fibroblast mono-
layers and enzyme uptake allowed to proceed for 24
h at 378C. The medium was then aspirated and the
cell layers washed three times with PBS before the
preparation and assay of cell extracts as previously
w xdescribed 7 .
2.7. In ˝i˝o enzyme uptake studies in rats
To determine the effect of anti-rh4S antibody on
enzyme distribution in vivo, normal control rats were
selected either on the basis of low titres to rh4S titre
.64 or were immunized with rh4S to induce antibody
 . 3responses titre 1 024 000 and then infused with H-
rh4S. Anti-rh4S antibodies were induced in normal
control animals by injection of 50 mg doses of
purified rh4S in Freund’s adjuvant. One injection of
Freund’s complete adjuvant 0.15 ml adjuvant with
.0.15 ml of rh4S in PBS was given subcutaneously as
a priming dose and followed by three subcutaneous
injections of rh4S in Freund’s incomplete adjuvant at
three weekly intervals. Plasma samples for antibody
titre determination were obtained by tail vein bleed-
ing of anaesthetized rats. Antibody titres in rats were
confirmed by ELISA of plasma antibodies, then the
animals were injected i.v. with 1 mgrkg of 3H-rh4S
 6 3 .1.25–1.8=10 dpm H-rh4S . Rats were sacrificed
at either 30 or 60 min after injection and analysed for
the distribution of 3H-rh4S in different tissues.
2.8. Granular fractionation of rat li˝er
Five grams of rat liver was placed in 45 ml of 0.25
 .M sucrose containing 1 mM EDTA, pH 7.5 48C
then dissected on ice and passaged through stainless
steel mesh. The cell suspension was centrifuged at
100=g for 5 s to remove aggregates and connective
tissue, and the supernatant then recentrifuged at 200
=g for 10 min at 48C. The resulting pellet was
resuspended to 10 ml in 0.25 M sucrose containing 1
 .mM EDTA, pH 7.5 48C and homogenized in a
Potter-Elalijem using 5 strokes. The homogenate was
then centrifuged at 200=g for 10 min to remove the
cellular debris and the supernatant passed through a
23 gauge needle to dissociate any adhering or-
ganelles. This granular fraction was then separated on
 .either a 10% Percoll gradient 30 min experiment or
 .18% Percoll gradient 60 min experiment and as-
w xsayed as previously described 28 .
2.9. Detection of rh4S acti˝ity in rat tissue extracts
Rat tissue extracts were prepared as previously
w xdescribed for feline tissues 20 . An enzyme im-
munobinding assay was used to specifically detect 4S
activity. The procedure used was as described previ-
w xously 29 , except that an affinity purified sheep
anti-mouse immunoglobulin antibody 1 mgrwell in
.0.1 M NaHCO pH 8.5 was bound to each well of a3
96-well polyvinylchloride plate, before the addition
of a monoclonal antibody which specifically reacts
 w xwith h4S 4-S F66 20 in this case as hybridoma
.culture supernatant . Antibody bound rh4S was de-
tected with MUS substrate and the results expressed
as nmolrmin g of tissue wet weight.
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2.10. Detection of 3H-rh4S in tissue extracts
To determine the level of 3H-rh4S in different
tissues, samples were dissected into small fragments
and solubilized overnight at 228C in 1 M NaOH 5
.mlrg of tissue . 200 ml of sample was neutralized
with HCl then mixed with 500 ml of NCS tissue
 .solubilizerrisopropanol 1:2 vrv for 15 min at 228C.
100 ml of 30% H O was then added, mixed and2 2
allowed to incubate for 60 min at 228C. Optiphase
 .‘Hi Safe 3’ liquid scintillant 15 ml was then added
and the samples counted on a Wallac liquid scintilla-
tion counter. Results were expressed as dpmrg of
tissue wet weight.
3. Results
3.1. Feline and human antibody reacti˝ity to rh4S
Plasma antibody titres to rh4S were detected in
 .both untreated MPS VI titre 8,390"7,277 and
 .  .normal control cats titre 10 343"13 846 Fig. 1 .
There was no significant difference between the reac-
tivity of plasma, from either untreated MPS VI ns
.  .20 or normal control cats ns33 , with rh4S
 .Tukey-B test; Fig. 1 . There was also no significant
difference between the reactivity of plasma from
eleven untreated MPS VI and normal control cats,
with rf4S when compared to rh4S Student’s t-test,
.Ps0.421, data not shown . The mean of plasma
titres to rh4S, was higher for rh4S treated MPS VI
 .cats ns17, 173 397"351 150, Fig. 1 when com-
pared to either untreated MPS VI or normal control
cats. This difference was statistically significant
 .Tukey-B test, Ps0.05 . However, 13 of 17 MPS
VI cats which were treated with rh4S, had anti-rh4S
antibody titres less than 44 000 the upper limit for
.normal control cats, Fig. 1 , after 3–15 mth of either
weekly or bi-weekly rh4S infusions, whereas four
rh4S treated MPS VI cats had anti-rh4S antibody
titres above the upper limit for normal control cats
 .Fig. 1 . One of the latter four cats was treated from
birth by s.c. injection of rh4S, while two others had
i.v. ERT initiated at either 2 or 7 mth after birth.
Only one of fourteen cats treated from birth by i.v.
Fig. 1. Antibody titres to rh4S in cats and humans. Untreated MPS VI and normal control, cats and humans were not injected with rh4S.
MPS VI treated cats received doses of 0.5–5 mgrkg of rh4S, at either 0.5, 1, or 2 weekly intervals. Plasma samples were isolated and
tested as described in Section 2. Results represent the highest anti-rh4S antibody titre recorded from monthly measurements. The numbers
on the figure represent the number of samples with that antibody titre. Statistical analysis of the anti-rh4S antibody titres in cats,
demonstrated a difference between normal control cats and MPS VI treated cats, and a difference between untreated MPS VI cats and
 .MPS VI treated cats Tukey-B test, Ps0.05 . There was no significant difference between normal control cat, untreated MPS VI cat and
normal control human plasma antibody titres to rh4S. Untreated human MPS VI patient plasma had significantly lower antibody titres to
 .rh4S compared to both normal control humans and any of the cat groups Tukey-B test, Ps0.05 .
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infusion had an anti-rh4S titre higher than the range
for either untreated MPS VI cats or normal control
cats. Taken as a subgroup of rh4S ERT treated cats,
the cats treated from birth by iv infusion had anti-rh4S
antibody titres which were not significantly different
from either untreated MPS VI or normal control cats
 .Tukey-B test . In experiments involving the MPS VI
cats treated with iv rh4S from 2 and 7 mth of age
 .Fig. 2 , a progressive increase in antibody titre was
observed during treatment, reaching maximal titres of
 .  .either 64 000 cat a84 or 1 024 000 cat a40 . Cats
which produced antibody titres to rh4S after ERT had
 .similar titres to both rh4S and rf4S data not shown .
Antibodies with reactivity to rh4S were also de-
tected in normal control human plasma Fig. 1: titre
.5,322"5,392 and human MPS VI patient plasma
 .Fig. 1: titre 681"668 . There was a significant
 .difference Tukey-B test, Ps0.05 , between the
anti-rh4S antibody titres for untreated human MPS
VI patient plasma and either normal control human
plasma or any of the cat plasma antibody titres ie.
either normal control, or MPS VI, or MPS VI ERT
.treated cats . There was no significant difference
between the antibody titres to rh4S for either normal
control human plasma, or normal control cat plasma
or untreated MPS VI cat plasma. Notably, a human
MPS VI patient with a truncation mutation which
resulted in no detectable 4S protein still had plasma
 .antibody reactivity to rh4S titre 160 .
Immunoblotting to detect rh4S, was performed
using feline plasma from rh4S ERT treated MPS VI
 .cats titre 1 024 000, Fig. 3a and untreated MPS VI
 .cats titres 16 000 and 2,048 . Immunoblot reactivity
to rh4S was only detected with the antibodies from
 .the MPS VI cats treated with rh4S Fig. 3a , with no
detectable reactivity to rh4S observed for the un-
 .treated MPS VI cats data not shown . Immunoblot
reactivity to rh4S was also observed for plasma from
 .high titre immunized rats, but little or no reactivity
was observed with low titre non-immune rat plasma.
3.2. Clinicalr immunological response of cats to
infused rh4S
All cats demonstrated to a lesser or greater extent
signs of adverse responses to infused rh4S at some
point during ERT treatment. Responses did not ap-
pear to correlate with the level of antibody titre but
tended to be more obvious in cats treated with 5
mgrkg of rh4S. Symptoms of responding cats in-
cluded trembling, ear scratching, increased respira-
tory rate, pyrexia, anxiety, cyanosis, vomiting, diar-
rhoea, and respiratory distress. In most cases re-
sponses were limited to ear scratching and vomiting,
Fig. 2. Development of antibody titres to rh4S, in rh4S infused MPS VI cats. Antibody titres to rh4S were determined on plasma samples
 .from two MPS VI cats following the initiation of long term rh4S ERT. Titres were monitored at monthly intervals. Cat a 40 – B – and
 .cat a84 – I – received rh4S iv at 1 mgrkg each fortnight and treatment was initiated at either 7 mth or 2 mth of age, respectively.
Plasma samples were prepared and assayed by ELISA as described in Section 2.
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Fig. 3. Immunoblot analysis of anti-rh4S antibodies from MPS
 .  .VI ERT treated cats a and high and low titre rats b . 5 mg of
rh4S was electrophoresed per lane by SDS-PAGE and transferred
to nitrocellulose membrane for immunoblotting. a. Immunoblots
 .from two MPS VI rh4S treated cats titres 1 024000, lanes 1–2 ,
while two untreated MPS VI cats did not react titre 16000 and
.  .2,048: data not shown . b. A 4-sulfatase protein stain lane 1 ,
 .and immunoblots from three low titre rats lanes 2–4 and three
 .high titre rats lanes 5–7 .
with only a few cats showing severe reactions involv-
ing all of the described symptoms. Responding cats
were pre-treated with Periactinw, NiraminewrPiri-
tonw, and Solucortef w as described in Materials and
Methods and were infused with rh4S at no more than
5 mlrkg per h, which appeared to reduce responsive-
ness. In cases where reactivity was suspected, infu-
sion was stopped and resumed 60 min later.
3.3. Effect of anti-rh4S antibody on rh4S uptake in
fibroblasts
rh4S uptake experiments were conducted in feline
fibroblasts, in the presence or absence of anti-rh4S
antibody from an rh4S treated MPS VI cat cat a40,
.titre 1 024 000; Table 1 . The incubation of rh4S with
feline fibroblasts resulted in high levels of 4S uptake
over 3 days. The addition of plasma antibody to rh4S
prior to uptake, reduced the levels of active rh4S
detected in cell extracts. Increasing the concentration
of rh4S relative to the concentration of antibody
added, partially overcame the observed affect on
 .uptake Table 1 .
3.4. Modification of antibody titre to rh4S after in
˝i˝o injection of rh4S protein
The level of anti-rh4S antibody was monitored in
an MPS VI cat treated with rh4S cat a40, titre
.1 024 000 , following the iv infusion of a 1 mgrkg
 .dose of rh4S Fig. 4 . The plasma sample taken
immediately prior to the injection of the rh4S, had an
antibody titre of 1 024 000. The volume of the rh4S
Table 1
Antibody inhibition of the uptake of active rh4S into feline fibroblasts
 .4S activity nmolrmin per mg
Conditions 10 nmolrmin per ml rh4S 10 nmolrmin per ml 30 nmolrmin per ml rh4S 30 nmolrmin per ml
no antibody rh4sqantibody no antibody rh4sqantibody
 .Time h
0 32 32 32 32
24 168 47 149 78
42 227 43 336 162
68 426 74 438 333
2 w xFeline fibroblasts were cultured in 25 cm culture dishes as previously described 6 . Fibroblasts were incubated for the specified times in
 .the presence of either 10 or 30 nmolrmin per ml in 5 ml total of rh4S, in basal modified eagle’s medium containing 10% heat
 .inactivated fetal calf serum. qAntibody represents cultures treated with plasma antibodies from a rh4S treated cat cat a40 , where the
 .final dilution of feline plasma was 1:20 i.e. titre of 50 000 from original titre of 1 024 000 .
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 .Fig. 4. In vivo depletion of rh4S reactive antibodies from circulation. rh4S was injected into cat a 40 1 mgrkg, iv and the effect on the
 .  .  .anti-rh4S antibody titre monitored at time zero – B – , 2 min – ( – and 60 min – I – after injection. Plasma samples were isolated
and tested by ELISA as described in Section 2. Results are expressed as absorbance at 414 nm.
Table 2
Distribution of 3H-rh4S in a low titre rat and a high titre rat, 30 min after infusion
Organ Low titre High titre
)) )) .  .  .  .  .  .dpmrg nmolrmin per g dpmrnmol per min dpmrg nmolrmin perrg dpmrnmol per min
liver 77 968 471 166 59 700 4.8 12 438
spleen 42 271 250 169 30 567 2.4 12 736
kidney 2,105 18 117 466 0.3 1,553
lung 1,125 1.6 703 22 127 1.3 17 020
heart 475 3 158 962 0.3 3,207
lymph node 868 3.5 248 2,375 0.4 5,938
 . 6 3  .Rats 270–280 g , received 1.25=10 dpm H-rh4S 76 dpmrnmol per min; 49 000 nmolrmin per mg as a single i.v. injection and
 .  .were sacrificed after 30 min. The low titre rat titre 64 received no previous injections of rh4S. The high titre rat titre 1 024 000 was
immunized with rh4S, given as four 50 mg injections at 2–3 wk intervals. Results are expressed as dpmrgm for 3H-rh4S radioactivity or
as nmolrmin per g for 4S activity. )), represents the ratio of dpmrgm to nmolrmin per g and is expressed as dpmrnmol per min.
Table 3
Distribution of 3H-rh4S in low and high titre rats, 60 min after infusion
Organ Low titre High titre
)) )) .  .  .  .  .  .dpmrg nmolrmin per g dpmrnmol per min dpmrg nmolrmin per g dpmrnmol per min
liver 59,020"2,216 279"17 211 51 561"8,136 17"4.9 3,033
spleen 26,413"5,233 124"43 213 20 368"3,481 4"1.7 5,092
kidney 1,947"888 5"1.5 389 2,460"1,768 0.8"0.1 3,075
lung 2,893"587 8"8.7 361 27 664"13 738 8"3.6 3,458
heart 1,932"267 2.5"0.8 772 2,652"1,407 0.6"0.2 4,420
lymph node 3,405"3,844 3.7"1.2 920 2,526"1,820 1"0.1 2,526
 . 6 3  .Rats 240–260 g , received 1.8=10 dpm H-rh4S 44 dpmrnmol per min; 54 000 nmolrmin per mg as a single i.v. injection and were
 . sacrificed after 60 min. The low titre rats ns3, titre 64 received no previous injections of rh4S. The high titre rats ns3, titre
.1 024 000 were immunized with rh4S, given as four 50 mg injections at 2–3 wk intervals. Results are expressed as dpmrg"SD for
3H-rh4S radioactivity or as nmolrmin per g"SD for 4S activity. )), represents the ratio of dpmrg to nmolrmin per g and is expressed
as dpmrnmol per min.
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infusion was less than 1% of the cats total blood
volume. Two min after the rh4S infusion, a plasma
sample showed an antibody titre of 2,048, suggesting
the removal of most of the anti-rh4S antibody from
circulation. The antibody titre remained at this level
or lower for at least 1 h. This experiment was re-
peated in another MPS VI cat treated with rh4S titre
.8,092 , where rh4S infusion resulted in a titre of
4,096 at 2 min after infusion and a titre of 2,048 at 60
min after rh4S infusion.
3.5. The distribution of infused 3H-rh4S in low and
high titre rats
To determine the distribution of rh4S in low titre
 .  .titre 64 and high titre rats titre 1 024 000 , animals
were infused with 3H-rh4S and sacrificed at either 30
min or 60 min after enzyme infusion.
Thirty min after the infusion of 3H-rh4S, high
levels of radiolabel and rh4S activity were detected in
 .the liver and spleen of a low titre rat Table 2 .
Lower but detectable levels of active 3H-rh4S were
also detected in kidney, lung, heart and lymph node.
In a high compared to a low titre rat, similar but
slightly reduced levels of 3H-rh4S radiolabel were
detected in liver, spleen, and kidney, but a dramatic
increase in radiolabel was observed in the lung Ta-
.ble 2 . In addition, the level of rh4S activity in all
tissues from the high titre rat were reduced compared
to the level detected in the same tissues from the low
titre rat. This was reflected as a higher ratio of
radiolabel to rh4S activity in tissues from the high
 .compared to the low titre rat Table 2 .
Sixty min after the infusion of 3H-rh4S a very
similar pattern of 3H-rh4S radiolabel and activity was
 .observed Table 3 , when compared to that observed
 .for the 30 minute experiment Table 2 . Thus, high
titre rats had increased levels of radiolabel in the lung
compared to low titre rats and all of the high titre rat
tissues had low levels of rh4S activity compared to
 .the amount of radiolabel detected Table 3 . The
major difference between the 30 and 60 min experi-
ments, was that the ratios of radioactivity to rh4S
activity in liver, spleen and lung from the 30 min
 .high titre rat Table 2 , were high compared to the
other tissues in the same rat and high compared to the
 .same tissues in the 60 min high titre rats Table 3 .
 .Fig. 5. Granular fractionation 11% Percoll gradient of rat liver
from a high titre rat and a low titre rat, 30 min after the infusion
of 3H-rh4S. a. Distribution of 3H-rh4S radiolabel in the low titre
 .  .rat – B – and the high titre rat – I – , and results are ex-
pressed as dpm per 1 ml fraction from the Percoll gradient. b.
 .Distribution of rh4S activity in the low titre rat – B – and the
 .high titre rat – I – . c. Distribution of b-hexosaminidase activ-
ity in the same two gradients.
3.6. Granular fractionation of rat li˝er from high and
low titre rats infused with 3H-rh4S
To determine the intracellular fate of rh4S in the
presence and absence of anti-rh4S antibody, high and
low titre rats were infused with 3H-rh4S and the liver
isolated and prepared for granular fractionation.
In the rat sacrificed 30 min after the infusion of
3H-rh4S, Percoll separation of rat liver granular frac-
tion demonstrated a different intracellular distribution
 .in the high compared to the low titre rat Fig. 5 . For
the low titre rat, the 3H-rh4S radiolabel was detected
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 .Fig. 6. Granular fractionation 18% Percoll gradient of rat liver from three high titre rats and three low titre rats, 60 min after the infusion
of 3H-rh4S. Individual rats are represented by either – B –, – ( –, or – I –. a. Distribution of 3H-rh4S radiolabel in Percoll granular
 w x.fractionation’s from three separate low titre rats. b. Distribution of rh4S measured by an immunobinding assay, 29 activity in Percoll
granular fractionation’s from three separate low titre rats. c. Distribution of 3H-rh4S radiolabel in Percoll granular fractionation’s from
 w x.three separate high titre rats. d. Distribution of rh4S activity measured by an immunobinding assay, 29 in Percoll granular
fractionation’s from three separate high titre rats. In all six granular fractionation’s of liver from the low and high titre rats there was an
 .almost identical pattern for the distribution of b-hexosaminidase activity, and is represented in e which shows the distribution in the
three high titre rats.
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in the high density fractions of the gradient Fig. 5a,
.fractions 13–16 which are characteristic of lyso-
somes and also colocalized with b-hexosaminidase
 .activity Fig. 5c . While the high titre rat had a
similar level of radiolabel in the gradient, a major
peak was observed in lower density fractions Fig.
.5a, fractions 10–13 , with only some of the radiola-
bel detected in fractions coincident with b-hexosa-
 .minidase activity Fractions 13–16 . The rh4S activ-
ity colocalized with the radiolabel for the low titre rat
but only very low levels of rh4S activity were de-
tected in the Percoll gradient for the high titre rat,
 .indicating the enzyme had been inactivated Fig. 5b .
In the low titre rats sacrificed 60 min after the
3 3  .infusion of H-rh4S, the H-rh4S radiolabel Fig. 6a
 .and enzyme activity Fig. 6b fractionated consis-
tently in high density organelles characteristic of
lysosomes. The 3H-rh4S was also coincident with
 .b-hexosaminidase activity Fig. 6e . In contrast, the
high titre rats showed reduced levels of radiolabel in
 .the gradients Fig. 6c and evidence of radiolabel in
 .lower density organelles Fig. 6c, fractions 7–13 .
Moreover, there was almost no detectable rh4S activ-
ity in the Percoll gradient fractions from these high
 .titre rats Fig. 6d .
4. Discussion
ERT can potentially result in a patient generating
an antibody response to the replacement protein,
particularly after successive enzyme infusion treat-
ments. The immediate concern for this immuno-
reactivity is the development of an anaphylactic reac-
tion, which can be life threatening to the patient.
Strategies to avert this type of clinical response in
patients have been suggested and include slow infu-
sion of enzyme and coadministration of anti-in-
flammatory drugs. Other possible problems due to the
generation of immunoreactivity may involve either
antibody inhibition of the replacement enzyme, or
inappropriate targeting, or enzyme degradation. These
are important concerns for the efficacy of ERT as a
proposed treatment for MPS patients.
As a prelude to ERT trials in human MPS VI
patients, we have investigated the levels of anti-rh4S
antibodies in plasma from normal control humans
and human MPS VI patients. Antibody titres to rh4S
were observed in both normal control human plasma
and untreated MPS VI patient plasma. It could be
speculated that the antibody reactivity to rh4S is due
to either the exposure of 4S protein to the immune
system or reflects a cross reactivity with another
antigen. The antibody titre to rh4S detected in an
MPS VI patient plasma which had no detectable 4S
 .protein truncation mutation indicates that the anti-4S
antibodies are probably not produced in response to
endogenous 4S protein, but more likely represent a
background level of anti-rh4S antibodies produced in
response to a cross reacting antigen. The anti-rh4S
titre levels were, however, higher in the normal con-
trol human plasma when compared to the human
MPS VI patient plasma. This may either reflect the
small number of samples tested in the human MPS
VI patient plasma or that the background level of
anti-rh4S antibodies can be increased by exposure to
endogenous 4S protein.
The feline model for MPS VI accurately reflects
the human disorder, with a very low level of f4S
w xprotein 27 and activity giving rise to a severe
w xclinical presentation 17,18,23–25 . Untreated MPS
VI and normal control cats were investigated for the
level of antibody to rh4S in plasma samples and the
development of antibody responses to ERT were
monitored in MPS VI cats treated with rh4S. Both
untreated MPS VI and normal control cats had anti-
body titres to rh4S and these antibodies reacted
equally well with rf4S, suggesting that the antibodies
are not just recognising species specific differences
between f4S and h4S. Together with the human
plasma data, this suggested that antibodies to 4S are
normally found in circulation, an observation which
may be important when considering the infusion of
4S protein for ERT.
We have previously reported immune responses in
w xsome MPS VI cats undergoing ERT with rh4S 17
and similar responses to human a-L-iduronidase have
w xbeen reported in an MPS I dog 12 . While it may be
argued that species specific antibodies may be gener-
ated by injecting rh4S into cats, it is postulated that
with the exception of linear sequence differences, the
w xminor structural difference between h4S and f4S 19
will approximate the conformational difference ob-
served between normal rh4S and mutant h4S protein
w xin MPS VI patients 7 . In addition, as discussed
above, MPS VI and normal control cat plasma had
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similar titres to both rh4S and rf4S. Moreover, evi-
dence from Gaucher studies indicate that human
Ceredasew administration into human patients still
w xresults in antibody responses in some cases 15,16 .
The MPS VI cats treated with rh4S had antibody
reactivities to rh4S which were significantly higher to
that observed in untreated MPS VI and normal con-
trol cats. Plasma antibodies from MPS VI cats treated
by rh4S ERT reacted equally with rh4S and rf4S
suggesting that this reactivity was not due to a species
 .specific response data not shown . However, not all
rh4S treated MPS VI cats responded with higher than
normal levels of anti-rh4S antibody production re-
flected by the high standard deviation in plasma titres
.for the MPS VI ERT treated cats . Three of the four
cats responding to rh4S, with titres greater than that
observed in untreated MPS VI and normal control
cats, were either treated by subcutaneous infusion of
 .  .rh4S ns1 or were treated after birth ns2 . For
 .MPS VI cats treated at birth by iv infusion ns14
only one cat responded with a titre greater than that
observed in untreated MPS VI and normal control
cats. Taken as a separate treatment group the MPS VI
cats treated from birth by iv infusion did not have
significantly different anti-rh4S titres compared to the
latter two control groups. Treating cats at birth may
be advantageous due to the potential to induce toler-
ance, but a larger sample size, particularly in the
post-birth treatment group, is required to confirm this
hypothesis. Considering the levels of anti-rh4S anti-
body titres in untreated MPS VI and normal control
cats, the number of cats responding to rh4S infusion
with titres higher than the normal range were surpris-
ingly few. Therefore, the background level of anti-
rh4S antibodies, observed in untreated MPS VI and
normal control cats, did not appear to predispose the
ERT treated MPS VI cats to respond to rh4S infusion
with higher than normal levels of anti-rh4S antibod-
ies. However, it is expected that some MPS VI cats
and human MPS VI patients will respond to ERT
with higher than normal levels of anti-rh4S antibod-
ies.
Most rh4S treated MPS VI cats showed at least
minor adverse clinical signs of hypersensitivity to
rh4S infusion at some stage during the course of
treatments, with a trend for cats treated with 5 mgrkg
of rh4S to show more reactive signs. The degree of
hypersensitivity did not appear to correlate with the
antibody titre level, suggesting that responsiveness
may be dependent on other parameters such as either
antibody isotype or antibody affinity, rather than the
amount of circulating antibody. In Gaucher patients,
hyperreactivity has been shown to be associated with
IgG antibodies rather than IgE antibodies and was
mediated by IgG immune complex formation and
w xcomplement fixation 16,30 . We have been unable to
confirm the isotype of the feline immunoglobulin
reacting with rh4S, as anti-cat subclass antibodies
were not available at the time of this study, but we
did show that plasma from high titre cats reacted on
immunoblots, suggesting the production of high affin-
ity antibody. The reactivity of high affinity antibodies
with rh4S by immunoblotting, was confirmed for
plasma antibodies from immunized rats,
Circulating antibodies to 4S could be detrimental
to successful ERT, by either inhibition of rh4S activ-
ity, or by mediating the premature degradation of
rh4S, or by affecting the targeting of the enzyme. In a
previous study 4S activity was inhibited by plasma
antibodies produced in a rh4S treated MPS VI cat
w x17 . Moreover, in enzyme uptake studies in feline
fibroblasts, the presence of antibody reduced the
detectable level of 4S in cell extracts. This reduced
uptake of active enzyme, could be due to either direct
inhibition of 4S activity, the effect of antibody on the
uptake process, or antibody induced degradation, or a
combination of mechanisms. In in vivo experiments
using cats with anti-rh4S antibody titres 1 024 000
.and 8,092 , anti-4S antibodies could be temporarily
removed from circulation by rh4S infusion, confirm-
ing the specificity of these antibodies for rh4S. This
also suggests that with slow infusion and appropriate
pre-medication to avoid hypersensitivity reactions,
that antibodies inducing either inappropriate target-
ing, or rh4S degradation, or rh4S inhibition could be
temporarily removed from circulation before the ad-
ministration of an effective therapeutic dose of en-
zyme.
Having demonstrated anti-4S antibodies in normal
control humans and cats, untreated MPS VI humans
and cats, and higher than normal anti-rh4S antibody
titres in some ERT treated MPS VI cats, a compara-
tive distribution study was performed in high and low
titre rats, to define the effects of circulating high titre
anti-rh4S antibodies on the targeting and fate of
infused 3H-rh4S. In high compared to low titre rats
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there was a difference in tissue distribution with high
titre antibody appearing to cause an increase in the
amount of 3H-rh4S trafficking to the lung. The depo-
sition of immune complexes in the lung may account
for some of the anaphylactic type reactions observed
in rh4S treated MPS VI cats. High titre antibody also
caused a marked reduction in enzyme activity of the
3H-rh4S in all of the tissues tested, indicating that
this level of antibody production may have a direct
effect on the efficacy of treatment.
The internalization of similar levels of 3H-rh4S
radiolabel into granular fractions from both high and
low titre rats, at 30 min after enzyme infusion, sug-
gests that the antibody did not inhibit rh4S uptake.
Rapid distribution of infused rh4S to the lysosomal
compartment was observed in low titre rats indicating
that receptor mediated uptake and targetingrtraffick-
ing to the lysosome is an extremely rapid process.
This is consistent with our previous observations
which showed a very short half life for the clearance,
w xin cats, of infused rh4S from the circulation 17 . In
contrast to the low titre rats, much of the 3H-rh4S did
not appear to reach the lysosomal compartment in
high titre rats, presumably due to the attached anti-
body.
While the intracellular targeting and trafficking of
3H-rh4S was different in high titre compared to low
titre animals, the associated effect on enzyme activity
was striking. The rh4S was rapidly inactivated
throughout the Percoll gradient, even for the radiola-
beled material which had apparently reached the
lysosomal compartment in the 30 minute experiment.
The reduction of radiolabel in the Percoll gradients
from high compared to low titre rats at 60 min after
enzyme infusion, suggested that the rh4S was either
degraded or removed from the vacuolar compartment.
Whatever the mechanism for removal of the 3H-rh4S
from the vacuolar compartment, the process appeared
to be rapid, with high titre rats at 60 min having
markedly reduced levels of the radiolabel in the
organelle fractions, when compared to both 30 and 60
min low titre rats and the 30 min high titre rat.
The generation of antibodies in MPS patients, in
response to ERT, would appear to have very impor-
tant implications for the efficacy of the treatment. It
is expected that even low levels of antibody may
result in some of the replacement protein failing to
reach the appropriate site in an active and stable
form. The current findings imply that further strate-
gies may be required to avert the production of
specific high titre antibodies in order to avoid the
potential detrimental effects on treatment efficacy.
Possible strategies to avoid the generation of antibod-
ies to a replacement protein include induction of
tolerance, immune suppression, coating the enzyme
with polyethylene glycol, increased sialylation of the
protein, and liposome encapsulation.
The current study indicates that antibody can alter
the tissue distribution of infused rh4S enzyme and
can inactivate and result in the rapid degradation of
internalized rh4S. Moreover the intracellular distribu-
tion of rh4S was different in high and low titre rats
suggesting that the antibody bound rh4S may be
directed to an intracellular organelle which is distinct
from the lysosomal compartment. The site of 4S
degradation could be the recently identified MIIC
compartment that contains class II antigen, and which
w xhas been implicated in antigen processing 31,32 . It
would then be speculated that antibody attachment to
rh4S is responsible for altered intracellular targeting
to this compartment, as well as for initiating the
ensuing degradation process. The current study has
demonstrated that antibody development may have
significant implications toward the efficacy of ERT
in MPS VI patients.
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